Skip to main content

Main menu

  • HOME
  • ONLINE FIRST
  • CURRENT ISSUE
  • ALL ISSUES
  • AUTHORS & REVIEWERS
  • SUBSCRIBE
  • BJGP LIFE
  • MORE
    • About BJGP
    • Conference
    • Advertising
    • eLetters
    • Alerts
    • Video
    • Audio
    • Librarian information
    • Resilience
    • COVID-19 Clinical Solutions
  • RCGP
    • BJGP for RCGP members
    • BJGP Open
    • RCGP eLearning
    • InnovAIT Journal
    • Jobs and careers

User menu

  • Subscriptions
  • Alerts
  • Log in

Search

  • Advanced search
British Journal of General Practice
Intended for Healthcare Professionals
  • RCGP
    • BJGP for RCGP members
    • BJGP Open
    • RCGP eLearning
    • InnovAIT Journal
    • Jobs and careers
  • Subscriptions
  • Alerts
  • Log in
  • Follow bjgp on Twitter
  • Visit bjgp on Facebook
  • Blog
  • Listen to BJGP podcast
  • Subscribe BJGP on YouTube
Intended for Healthcare Professionals
British Journal of General Practice

Advanced Search

  • HOME
  • ONLINE FIRST
  • CURRENT ISSUE
  • ALL ISSUES
  • AUTHORS & REVIEWERS
  • SUBSCRIBE
  • BJGP LIFE
  • MORE
    • About BJGP
    • Conference
    • Advertising
    • eLetters
    • Alerts
    • Video
    • Audio
    • Librarian information
    • Resilience
    • COVID-19 Clinical Solutions
Editorials

Statins for all: should patients who have migraine with aura be on a statin?

David Kernick
British Journal of General Practice 2015; 65 (640): 571-572. DOI: https://doi.org/10.3399/bjgp15X687253
David Kernick
St Thomas Health Centre, Exeter.
Roles: GP
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info
  • eLetters
  • PDF
Loading

Over the past decade there has been increasing recognition of the importance of statins in preventing cardiovascular disease and, despite concerns of potential side-effects, in their use in populations who are at a lower risk.

Inflammatory conditions are known to increase cardiovascular risk, and rheumatoid arthritis is now recognised as a relevant factor in risk algorithms. Migraine is fundamentally an inflammatory problem triggered by activation of the trigeminal neurovascular complex. Should this be included in a risk analysis?

BACKGROUND

Migraine affects 7.6% of males and 18.3% of females in England.1 Thirty per cent of patients with migraine, or ‘migraineurs’, have migraine with aura, a transitory motor or sensory, positive or negative, neurological phenomenon lasting <1 hour that typically precedes the headache. An aura is a wave of depolarisation that travels at 3 mm/minute across the cortex and is associated with an oligaemia that is less than the ischaemic threshold. The relationship between depolarisation, blood flow, and headache is not understood.

Although epidemiology is confounded by migraine diagnostic concerns, a recent meta-analysis of migraine and cardiovascular disease found significant risks for those who had aura, but no increased risk for migraine without aura. Ischaemic stroke was the main concern with an overall odds ratio (OR) of 2.51 (95% confidence interval [CI] = 1.52 to 4.14) with increased risks for females (OR 2.89; 95% CI = 2.43 to 3.45).2 Another meta-analysis showed increased risk in patients aged <45 years (OR 2.65; 95% CI = 1.41 to 4.97), smokers (OR 9.03; 95% CI = 4.22 to 19.34), and females using combined oral contraception (OR 7.02; 95% CI = 1.51 to 32.68).3 The data on an association with ischaemic heart disease have been more variable, but recent studies have shown a doubling of risk for migraine with aura.4

Cardiovascular risks are higher in those who experience >12 attacks a year (OR 1.7; 95% CI = 1.1 to 2.8).5 Should migraine with aura be included in a formal risk assessment? If so, what should the multiplication factor be and should the frequency of migraine be taken into account?

POSSIBLE MECHANISMS RELATING MIGRAINE WITH AURA TO VASCULAR DISEASE

Although migraine with aura is associated with increase in risk factors, such as smoking, cholesterol, and blood pressure, these cannot account for the increased vascular risk, and the relationship is likely to be independent of other risk factors.6 Migraineurs who have aura demonstrate progressive white-matter hyperintensities on MRI, which are related to headache load. These lesions have a similar appearance to the microvascular changes that occur in older people, although surprisingly their exact nature has not been confirmed.7

The underlying mechanism that gives rise to vascular risk is unknown, but possibilities include the following.

  • Endothelial dysfunction. The endothelium is a complex organ that responds to a number of factors, including blood flow. A number of abnormal vascular biomarkers have been identified including endothelial microparticles that are thought to play a part in vascular control. However, studies on vascular reactivity have been mixed, without any formal conclusions.

  • Platelet abnormalities. Platelets of migraineurs show high levels of 5-hydroxytryptamine, a substance known to be implicated in the migraine process. They also show increased adherence. However, population studies have not been conclusive and there is no evidence that aspirin or clopidogrel have an impact on migraine frequency.

  • Microemboli. Migraineurs with aura have an increased incidence of patent right-to-left cardiac shunts, and retrospective analysis of closure in migraineurs for other reasons has shown significant benefit. The suggestion was that vasoactive substances or microemboli were bypassing the pulmonary circulation, which may act as a vascular filter. However, a controversial prospective randomised controlled trial showed no evidence of benefit of foramen closure.8

  • Drug induced. Triptans, widely used in migraine, have vasoconstrictive properties. However, a systematic review of observational studies showed no impact.8,9

IMPLICATIONS FOR CLINICAL PRACTICE

In the UK, based on a cost–utility analysis, the National Institute for Health and Care Excellence has recommended that statins are introduced when the 10-year risk of cardiovascular disease is 10%.10 The Framingham risk assessment tool has been superseded by QRISK®2.11

As studies give different estimates of risk, albeit all raised, and no definitive mechanisms or vascular biomarkers have been identified, a pragmatic approach taking an approximate average of existing studies seems indicated. Inevitably this will be a subjective judgement, but until further data are forthcoming my suggestion is that, as a basis for discussion with the patient, the 10-year risk is multiplied by 2.5 for female and 1.5 for male migraineurs with aura. Lower treatment thresholds should be considered for younger patients, and for migraineurs who experience >12 attacks a year, as risks are likely to be higher in these groups. The importance of other risk factors and in particular smoking should be emphasised.

What does this mean in practice for the 4% of the population who have migraine with aura? Examples of clinical profiles and their risks derived from QRISK®2 are shown in Table 1. This reflects the fact that underlying vascular risk remains greater in males and increases with age, and the additional workload for GPs in patients without other risk factors is likely to be small. Due to our limited knowledge of the mechanisms through which migraine operate these calculations will be imprecise, but are a useful starting point. They alert us to the fact that, in the absence of other risk factors, age still remains the most significant consideration.

View this table:
  • View inline
  • View popup
Table 1.

10-year risk of cardiovascular disease derived from QRISK®2 for migraineurs with aura versus no migraine in the absence of any other risk factorsa

  • © British Journal of General Practice 2015

REFERENCES

  1. 1.↵
    1. Steiner T,
    2. Scher A,
    3. Stewart F,
    4. et al.
    (2003) The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. Cephalalgia 23(7):519–527.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Spector J,
    2. Kahn S,
    3. Jones M,
    4. et al.
    (2010) Migraine headache and ischemic stroke risk: an updated meta-analysis. Am J Med 123(7):612–624.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Schurks M,
    2. Rist P,
    3. Bigal M,
    4. et al.
    (2009) Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ 339:b3914.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Wang Y,
    2. Lin C,
    3. Ho Y,
    4. et al.
    (2014) Increased risk of ischemic heart disease in young patients with migraine: a population-based, propensity score-matched, longitudinal follow-up study. Int J Cardiol 172(1):213–216.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. MacClellan L,
    2. Giles L,
    3. Cole J,
    4. et al.
    (2007) Probable migraine with visual aura and risk of ischaemic stroke: the stroke prevention in young women study. Stroke 38(9):2438–2445.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Sacco S,
    2. Pistoia F,
    3. Degan D,
    4. Carolei A
    (2014) Conventional vascular risk factors: their role in the association between migraine and cardiovascular disease. Cephalalgia 35(2):146–164.
    OpenUrl
  7. 7.↵
    1. Erdelyi S,
    2. Aradi M,
    3. Kamson D,
    4. et al.
    (2015) Changes of migraine related white-matter hyper intensities after three years: a longitudinal MRI study. Headache 55(1):55–69.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Dowson AJ,
    2. Wilmshurst P,
    3. Muir KW,
    4. et al.
    (2005) A prospective, multicentre, double-blind, placebo-controlled study to evaluate the efficacy of patent foramen ovale closure for the resolution of refractory migraine headache (the MIST Study): prevalence and size of shunts. Headache Care 2(4):223–227.
    OpenUrlCrossRef
  9. 9.↵
    1. Roberto G,
    2. Raschi E,
    3. Piccinni C,
    4. et al.
    (2015) Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies. Cephalalgia 35(2):118–131.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. National Institute for Health and Care Excellence
    (2014) Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease CG181 (NICE, London) https://www.nice.org.uk/guidance/cg181 (accessed 22 Sep 2015).
  11. 11.↵
    1. Hippisley-Cox J,
    2. Coupland C,
    3. Vinogradova Y
    (2008) Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 336(7659):1475–1482.
    OpenUrlAbstract/FREE Full Text
Back to top
Previous ArticleNext Article

In this issue

British Journal of General Practice: 65 (640)
British Journal of General Practice
Vol. 65, Issue 640
November 2015
  • Table of Contents
  • Index by author
Download PDF
Email Article

Thank you for recommending British Journal of General Practice.

NOTE: We only request your email address so that the person to whom you are recommending the page knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Statins for all: should patients who have migraine with aura be on a statin?
(Your Name) has forwarded a page to you from British Journal of General Practice
(Your Name) thought you would like to see this page from British Journal of General Practice.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Statins for all: should patients who have migraine with aura be on a statin?
David Kernick
British Journal of General Practice 2015; 65 (640): 571-572. DOI: 10.3399/bjgp15X687253

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Statins for all: should patients who have migraine with aura be on a statin?
David Kernick
British Journal of General Practice 2015; 65 (640): 571-572. DOI: 10.3399/bjgp15X687253
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
  • Mendeley logo Mendeley

Jump to section

  • Top
  • Article
    • BACKGROUND
    • POSSIBLE MECHANISMS RELATING MIGRAINE WITH AURA TO VASCULAR DISEASE
    • IMPLICATIONS FOR CLINICAL PRACTICE
    • REFERENCES
  • Figures & Data
  • Info
  • eLetters
  • PDF

More in this TOC Section

  • Inclusion and diversity at the BJGP and BJGP Open
  • People, humility, and ambition: our vision for the future of general practice
  • General practice — the integrating discipline
Show more Editorials

Related Articles

Cited By...

Intended for Healthcare Professionals

BJGP Life

BJGP Open

 

Tweets by @BJGPjournal

 
 

British Journal of General Practice

NAVIGATE

  • Home
  • Current Issue
  • All Issues
  • Online First
  • Authors & reviewers

RCGP

  • BJGP for RCGP members
  • BJGP Open
  • RCGP eLearning
  • InnovAiT Journal
  • Jobs and careers

MY ACCOUNT

  • RCGP members' login
  • Subscriber login
  • Activate subscription
  • Terms and conditions

NEWS AND UPDATES

  • About BJGP
  • Alerts
  • RSS feeds
  • Facebook
  • Twitter

AUTHORS & REVIEWERS

  • Submit an article
  • Writing for BJGP: research
  • Writing for BJGP: other sections
  • BJGP editorial process & policies
  • BJGP ethical guidelines
  • Peer review for BJGP

CUSTOMER SERVICES

  • Advertising
  • Contact subscription agent
  • Copyright
  • Librarian information

CONTRIBUTE

  • BJGP Life
  • eLetters
  • Feedback

CONTACT US

BJGP Journal Office
RCGP
30 Euston Square
London NW1 2FB
Tel: +44 (0)20 3188 7400
Email: journal@rcgp.org.uk

British Journal of General Practice is an editorially-independent publication of the Royal College of General Practitioners
© 2023 British Journal of General Practice

Print ISSN: 0960-1643
Online ISSN: 1478-5242